ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2021
Patient Perceptions of and Preferences Between Characteristics of Injectable Diabetes Treatments.
Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- The Development of a Syringe-Based Insulin Applicator Using a Biodesign-Based Methodology.Biomimetics (Basel, Switzerland) · 2026Article
- Ease of Use of the Lebrikizumab Prefilled Pen for Individuals with Atopic Dermatitis.Patient preference and adherence · 2026Article
- Health Utility Decrement of Injection Treatment-Related Attributes Using Time Trade-Off Among Type 2 Diabetes Patients: A Vignette-Based Study.PharmacoEconomics - open · 2026Article
- The power of insulin education: enhancing pain and treatment perception in adult type 2 diabetes patients.Journal of diabetes and metabolic disorders · 2025Article
- Tirzepatide Improved Health-Related Quality of Life Compared with Insulin Lispro in Basal Insulin-Treated Adults with Type 2 Diabetes and Inadequate Glycaemic Control: A Randomised Controlled Phase 3b Trial (SURPASS-6).Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024Article
- Satisfaction with the Injection Experience of a New, Citrate-Free Formulation of Ixekizumab.Advances in therapy · 2024Observational
- Physician Perceptions of Dose Escalation for Type 2 Diabetes Medications in the United States.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024Article
- Evaluating Patient and Provider Preferences for a Once-Weekly Basal Insulin in Adults with Type 2 Diabetes.Patient preference and adherence · 2024Article
- Patient perception towards shifting oral antihyperglycemic agents to injectable insulin and associated factors in the diabetes clinic of Tikur Anbessa specialized hospital: Cross-sectional study.Metabolism open · 2023Article
- Factors Affecting Performance of Insulin Pen Injector Technology: A Narrative Review.Journal of diabetes science and technology · 2023Review
- Patients' lived experiences of self-injectable diabetes treatment: A phenomenological study.Health SA = SA Gesondheid · 2023Article
- Development of an Insulin Pen is a Patient-Centric Multidisciplinary Undertaking: A Commentary.Journal of diabetes science and technology · 2022Article
- The Review of Insulin Pens-Past, Present, and Look to the Future.Frontiers in endocrinology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionThe administration of medications targeting type 2 diabetes mellitus (T2D) has evolved over time. As injection delivery systems continue to evolve, it is necessary to understand patients' perceptions of currently available treatments. The objective of this study was to examine the patient perspective of injectable treatment for T2D and identify characteristics of these treatments that are most important to patients.
methodsData were collected via an online survey study with a sample of individuals in the UK and US who were treated for T2D with injectable medication. The survey was designed to elicit perceptions of the treatment process for injectable glucagon-like peptide 1 (GLP-1) receptor agonists and insulin.
resultsThe sample included 504 participants (251 UK, 253 US). Approximately half (50.4%) were treated with a GLP-1 receptor agonist and half (49.6%) were treated with insulin. Respondents were presented with a list of 17 characteristics of injectable medication and asked to indicate which were most important to them. Respondents most frequently selected confidence in administering the correct dose (n = 300, 59.5%); ease of selecting the correct dose (n = 268, 53.2%); overall ease of using the injection device (n = 239, 47.4%); frequency of injections (n = 223, 44.2%); and ease of carrying the device when necessary to inject away from home (n = 190, 37.7%). Characteristics least frequently cited as important included dose escalation (n = 79, 15.7%); handling the needle (n = 74, 14.7%); connectivity to an electronic device (n = 70, 13.9%); and the time required to prepare and inject each dose (n = 62, 12.3%).
conclusionResults of this survey suggest that patients prioritize some attributes of injectable treatments over others. These findings may have implications for clinical practice and development of injection devices.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.